This site is intended for healthcare professionals
Drug news

Two analyses show Fycompa (Eisai) effective for Epilepsy

Read time: 1 mins
Last updated:11th May 2013
Published:11th May 2013
Source: Pharmawand

Two new analyses on clinical experience with Fycompa (perampanel), from Eisai, show it is effective and well tolerated in patients with difficult-to-treat partial Epilepsy. The results describe the first real life experiences of perampanel as an adjunctive therapy. In the first study, on 45 patients followed up for at least six months, 47% had a reduction in seizure frequency of at least 50% compared to baseline, and 16% became seizure free. 62% (n=28) of patients experienced adverse events.

In a second study of patients who had intractable epilepsy (52.6% with temporal lobe epilepsy) for an average of 23.7 years, and had previously been treated with an average number of nine AEDs, 21.1% experienced more than a 50% decrease of seizure frequency with perampanel, and a further five patients (26.3%) observed a positive effect, although less than a 50% reduction in seizure frequency. Four patients discontinued treatment. Data was presented at a meeting of the German and Austrian Societies for Epileptology and the Swiss League Against Epilepsy.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights